Predictmedix Stock Price, News & Analysis

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a clinical study set to begin in February 2022 at a North American hospital, aimed at validating its AI-driven Infectious Diseases Detection Solution. The study will utilize the company's Safe Entry Stations to screen staff and incoming patients for infectious diseases, including COVID-19. This step is crucial for FDA Class II medical device certification and commercial launch. Results will be published in a peer-reviewed journal. The study aims to enhance the AI algorithms and data collection, supporting the company's expansion in healthcare.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the results of a study on its AI technology for detecting alcohol and cannabis impairment, showing efficacy rates of 79-87% and 76-92% respectively. The company plans a clinical trial in February 2022 at a North American hospital to validate these findings further. The AI system is designed to be contactless, cost-effective, and capable of immediate results. Predictmedix is also seeking classification of its technology as a class II medical device in the US.

Predictmedix Inc. (CSE: PMED, OTCQB: PMEDF) announced the first placement of its Safe Entry Station at Ste. Anne's Spa in Ontario, enhancing health and safety for staff and guests. This collaboration with partners Juiceworks Exhibits and SBL Testing Technologies highlights Predictmedix's entry into the hospitality sector as demand for safe experiences rises amid ongoing COVID-19 challenges. The Safe Entry Station is designed to identify symptoms of infectious diseases, adding a crucial layer of safety in public spaces.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the successful launch of the ThuraPass Safe Entry Program at the 2021 Formula One United States Grand Prix. This program employs rapid AI-powered health screening technology to identify COVID-19 symptoms among event staff and attendees. During its first major deployment, over 400,000 people attended the event, and several staff members were flagged and sent home for recovery. The screening process takes about three seconds, enhancing safety in enclosed hospitality areas. This initiative aims to provide risk mitigation as indoor events resume.

Predictmedix Inc. has successfully deployed 15 Safe Entry Stations at the 2021 Formula 1 Aramco United States Grand Prix in Austin, Texas, aimed at enhancing health safety for attendees and catering staff. This deployment marks a significant revenue-generating initiative in partnership with JUICEWORKS EXHIBITS and CONNECTUS Global. The AI-powered stations quickly screen for COVID-19 symptoms, ensuring that only healthy individuals access hospitality areas. With over 100,000 attendees expected, this showcases Predictmedix's growing presence in the health screening market.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has successfully cleared SEC comments on its Form 20-F registration statement, submitted on June 17, 2021. This registration allows Predictmedix to list equity securities on a U.S. national stock exchange, thus enhancing its reporting and transparency. It is now required to file regular reports with the SEC, providing investors with insights into its business strategies, risk factors, and financial performance. The company aims for further capital market activities to generate long-term value for its shareholders.

Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a strategic partnership with Entertainment Bay, a major event production company in India. This collaboration aims to deploy Safe Entry Stations at Entertainment Bay events, enhancing health screening for infectious diseases like COVID-19. With over 100 events managed annually, Predictmedix anticipates generating approximately $1,000 per unit per day. The partnership is expected to significantly expand Predictmedix's footprint in the Indian live event market, promoting safer event environments.